Skip to main content
. 2024 Apr 30;19(4):645–659. doi: 10.1007/s11523-024-01061-0

Table 1.

Adverse events

GRADE 0 GRADE 1 GRADE 2 GRADE 3 GRADE 4 GRADE 5
Arterial hypertension 599 (72.8%) 65 (7.9%) 107 (13.0%) 52 (6.3%) 0 (0.0%) 0 (0.0%)
Fatigue 609 (74.0%) 145 (17.6%) 55 (6.7%) 14 (1.7%) 0 (0.0%) 0 (0.0%)
Decreased appetite 647 (78.6%) 112 (13.6%) 48 (5.8%) 16 (1.9%) 0 (0.0%) 0 (0.0%)
Proteinuria 579 (70.3%) 102 (12.4%) 85 (10.3%) 57 (6.9%) 0 (0.0%) 0 (0.0%)
Diarrhea 756 (91.9%) 48 (5.8%) 15 (1.8%) 4 (0.5%) 0 (0.0%) 0 (0.0%)
Hypothyroidism 779 (94.6%) 14 (1.7%) 27 (3.3%) 3 (0.4%) 0 (0.0%) 0 (0.0%)
Immunotoxicity 717 (87.1%) 54 (6.6%) 27 (3.3%) 21 (2.5%) 4 (0.5%) 0 (0.0%)
Other 659 (80.1%) 49 (5.9%) 57 (6.9%) 48 (5.8%) 9 (1.1%) 1 (0.1%)